Uygun, VedatOzsan, NazanDaloglu, HayriyeOzturkmen, SedaYalcin, KorayKarasu, GulsunYesilipek, Akif2023-01-122023-01-1220220925-57101865-3774https://doi.org/10.1007/s12185-021-03267-8https://hdl.handle.net/11454/76283EBV-associated lymphoproliferative disorders (LPDs) are common in hematopoietic stem cell transplantation (HSCT) with T-cell-depleted grafts, but are extremely rare in HSCT patients with T-cell-replete grafts with post-transplant cyclophosphamide (PTCy). Here we present the cases of two pediatric patients who developed EBV-related LPD after T-cell-replete haplo-HSCT with PTCy. One of these is the first reported case of EBV-positive mucocutaneous ulcer (EBVMCU) developing after PTCy. EBV-related diseases are rare in T-cell-replete haplo-HSCT patients with PTCy. However, in patients with risk factors, it is reasonable to screen for EBV viremia for LPD.en10.1007/s12185-021-03267-8info:eu-repo/semantics/closedAccessPost-transplant cyclophosphamideLymphoproliferative disorderEBV-positive mucocutaneous ulcerEpstein-Barr virusManagementBloodArticle1154600604WOS:0007228654000012-s2.0-8511995555234826107Q3Q4